Deep Track nominees get nod from Glass Lewis for Dynavax board

Proxy advisory firm Glass Lewis recommended Dynavax (DVAX) shareholders vote for two director nominees proposed by Deep Track Capital, a 14.82% shareholder, citing concerns over Dynavax's capital allocation strategy and a need for board members with capital markets experience. Glass Lewis highlighted Dynavax's high current ratio and substantial cash balance, questioning the timing of share repurchases and a recent capital raise, echoing Deep Track's concerns about overly conservative capital deployment; this follows a Q1 earnings miss despite strong revenue growth driven by HEPLISAV-B vaccine sales.

Analysis

Dynavax Technologies Corporation (DVAX) faces a significant governance challenge, underscored by proxy advisory firm Glass Lewis's recommendation for shareholders to support two director nominees from activist investor Deep Track Capital, which holds a 14.82% stake. This endorsement reflects concerns, shared by Deep Track, regarding Dynavax's strategic direction and what Glass Lewis described as an 'overly conservative' capital allocation strategy. This critique is supported by Dynavax's high current ratio of 11.93, a substantial cash balance, and questions surrounding the timing and scale of share repurchases and a recent capital raise despite ample reserves. Glass Lewis also highlighted a lack of directors with capital markets or institutional investor backgrounds on the current board. Operationally, Dynavax has demonstrated strong top-line performance, with revenue growth of 24.76% over the last twelve months and a 34% year-over-year increase in Q1 2025 revenue, primarily driven by a 36% growth in net sales of its HEPLISAV-B vaccine. However, this was contrasted by a significant Q1 2025 earnings per share miss, reporting -$0.77 compared to a forecasted $0.04, and profitability remains an ongoing concern. While Dynavax defends its long-term strategy, pointing to a 203% return to stockholders over the past five years and active R&D expansion, and maintains an InvestingPro 'GOOD' financial health score of 2.7 with strong cash flow metrics, the upcoming proxy vote on June 11, 2025, where Deep Track is contesting four board seats, is a critical juncture. The prevailing moderately negative sentiment and critical tone reflect these governance tensions and the earnings disappointment, despite Citizens JMP maintaining a Market Outperform rating, though with a reduced price target from $33.00 to $31.00.

Key Decisions for Investors

• Investors should closely monitor the outcome of the June 11, 2025, proxy vote, as potential board changes could significantly alter Dynavax's capital allocation strategy and overall strategic direction.
• Carefully weigh the company's robust revenue growth, particularly from its HEPLISAV-B vaccine, against the recent substantial earnings per share miss, persistent profitability challenges, and the governance overhang highlighted by activist pressure.
• Assess the implications of activist engagement and Glass Lewis's critique for future capital deployment, particularly concerning the utilization of the large cash balance and the potential for initiatives more directly aligned with shareholder value enhancement.